MedTrace Logo

Study of Immune Responses Induced by a HIV Vaccine

NCT01933685 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2019-09-19

No results posted yet for this study

Summary

The purpose of this study is to define the immune responses induced by a HIV vaccine, AIDSVAX B/E. Blood and mucosal samples will be collected to assess immune responses.

Conditions

  • HIV Infections

Interventions

BIOLOGICAL

AIDSVAX B/E

1 mL per injection (300 ug dose/antigen for a total of 600 ug/dose administered)

BIOLOGICAL

AIDSVAX B/E Placebo

1 mL per injection

Sponsors & Collaborators

  • National Institutes of Health (NIH)

    collaborator NIH

  • U.S. Army Medical Research and Development Command

    lead FED

Principal Investigators

  • Nittaya Phanuphak,, MD, PhD · Thai Red Cross AIDS Research Centre

  • Jintanat Ananworanich, MD, PhD · US Military HIV Research Program

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-07-03
Primary Completion
2016-05-24
Completion
2020-05-31

Countries

  • Thailand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01933685 on ClinicalTrials.gov